LEO Pharma has reported outcomes from the 16-week interim analysis of the Phase IIIb ADHAND trial of tralokinumab for hand atopic dermatitis (AD).

The trial aims to assess the safety and efficacy of tralokinumab 300mg administered biweekly as a single agent.

Apogee Therapeutics (NASDAQ:APGE) stock drops despite mid-stage trial success for APG777 in treating atopic dermatitis. Read ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

When somebody's coming in that has a known diagnosis of atopic dermatitis or eczema and things are really revved up still, if ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

This new study identifies key contributors to mental health decline in individuals with atopic dermatitis, highlighting the ...

So there's a lot of different studies looking at potential socioeconomic factors that may lead to somebody's increased risk ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

Spongiotic dermatitis describes skin inflammation that causes swelling, redness, and itching. It's most often associated with ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Investing.com -- Apogee (NASDAQ: APOG) Therapeutics, Inc. (NASDAQ: APGE) stock surged 24% on Monday after the clinical-stage biotechnology company announced positive 16-week data from its Phase 2 APEX ...